The stock of Guardant Health Inc (NASDAQ: GH) has decreased by -1.55 when compared to last closing price of 41.36. Despite this, the company has experienced a 2.47% gain in its stock price over the last five trading sessions. businesswire.com reported 2025-05-08 that PALO ALTO, Calif.–(BUSINESS WIRE)–Today TIME named to its 2025 TIME100 Health list co-CEOs Helmy Eltoukhy and AmirAli Talasaz of Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company. The list recognizes and honors the top 100 most influential people in global health this year. “The inclusion on TIME100 Health’s list is more than a personal honor,” said AmirAli Talasaz, Guardant Health co-CEO. “It is a recognition of the incredible technology that our Guardant team has buil.
Is It Worth Investing in Guardant Health Inc (NASDAQ: GH) Right Now?
Company’s 36-month beta value is 1.39.Analysts have differing opinions on the stock, with 15 analysts rating it as a “buy,” 7 as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for GH is 117.60M, and currently, short sellers hold a 6.56% ratio of that floaft. The average trading volume of GH on May 15, 2025 was 2.39M shares.
GH’s Market Performance
GH stock saw a decrease of 2.47% in the past week, with a monthly decline of -9.83% and a quarterly a decrease of -10.27%. The volatility ratio for the week is 5.30%, and the volatility levels for the last 30 days are 5.97% for Guardant Health Inc (GH). The simple moving average for the last 20 days is -8.62% for GH stock, with a simple moving average of 16.66% for the last 200 days.
Analysts’ Opinion of GH
Many brokerage firms have already submitted their reports for GH stocks, with Mizuho repeating the rating for GH by listing it as a “Outperform.” The predicted price for GH in the upcoming period, according to Mizuho is $55 based on the research report published on April 10, 2025 of the current year 2025.
Barclays, on the other hand, stated in their research note that they expect to see GH reach a price target of $60. The rating they have provided for GH stocks is “Overweight” according to the report published on January 23rd, 2025.
Guggenheim gave a rating of “Buy” to GH, setting the target price at $36 in the report published on June 28th of the previous year.
GH Trading at -6.65% from the 50-Day Moving Average
After a stumble in the market that brought GH to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -23.05% of loss for the given period.
Volatility was left at 5.97%, however, over the last 30 days, the volatility rate increased by 5.30%, as shares sank -9.21% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -1.83% lower at present.
During the last 5 trading sessions, GH rose by +2.47%, which changed the moving average for the period of 200-days by +23.39% in comparison to the 20-day moving average, which settled at $44.56. In addition, Guardant Health Inc saw 33.29% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at GH starting from Talasaz AmirAli, who sale 106,784 shares at the price of $49.01 back on May 01 ’25. After this action, Talasaz AmirAli now owns 2,202,672 shares of Guardant Health Inc, valued at $5,233,421 using the latest closing price.
Talasaz AmirAli, the Co-Chief Executive Officer of Guardant Health Inc, sale 13,932 shares at $50.47 during a trade that took place back on May 02 ’25, which means that Talasaz AmirAli is holding 2,188,740 shares at $703,151 based on the most recent closing price.
Stock Fundamentals for GH
Current profitability levels for the company are sitting at:
- -0.59 for the present operating margin
- 0.61 for the gross margin
The net margin for Guardant Health Inc stands at -0.54. The total capital return value is set at -0.41. Equity return is now at value -4584.47, with -27.33 for asset returns.
Based on Guardant Health Inc (GH), the company’s capital structure generated 1.24 points at debt to capital in total, while cash flow to debt ratio is standing at -0.21. The debt to equity ratio resting at -5.21. The interest coverage ratio of the stock is -166.83.
Currently, EBITDA for the company is -390.12 million with net debt to EBITDA at -1.53. When we switch over and look at the enterprise to sales, we see a ratio of 7.3. The receivables turnover for the company is 6.71for trailing twelve months and the total asset turnover is 0.58. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.11.
Conclusion
In a nutshell, Guardant Health Inc (GH) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
